Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
14
|
pubmed:dateCreated |
1982-7-19
|
pubmed:language |
dut
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0028-2162
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
3
|
pubmed:volume |
126
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
616-22
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6804879-Antineoplastic Agents,
pubmed-meshheading:6804879-Clinical Trials as Topic,
pubmed-meshheading:6804879-Drug Therapy, Combination,
pubmed-meshheading:6804879-Hodgkin Disease,
pubmed-meshheading:6804879-Humans,
pubmed-meshheading:6804879-Neoplasm Staging,
pubmed-meshheading:6804879-Radiotherapy, High-Energy,
pubmed-meshheading:6804879-Vinblastine
|
pubmed:year |
1982
|
pubmed:articleTitle |
[EORTC studies in Hodgkin's disease].
|
pubmed:publicationType |
Journal Article
|